Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); Final report of RTOG 89-01

International Journal of Radiation Oncology Biology Physics

Volumn 54, Issue 2, 2002, Pages 365-369

  Johnstone, David W ^a,e   Byhardt, Roger W ^b   Ettinger, David ^c   Scott, Charles B ^d  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RADIATION THERAPY ONCOLOGY GROUP   (United States)

^e UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Chemotherapy; Lung cancer; N2 disease; Radiotherapy; Surgery

Indexed keywords

CHEMOTHERAPY; PATIENT TREATMENT; RADIOTHERAPY; TUMORS;

LUNG CANCER;

ONCOLOGY;

CISPLATIN; MITOMYCIN A; VINBLASTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOCUMENTATION; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINOSCOPY; PHASE 3 CLINICAL TRIAL; PLEURA EMPYEMA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; RADIATION INJURY; RADIATION PNEUMONIA; RADIATION RESPONSE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SURGICAL MORTALITY; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; THORACOTOMY; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; PNEUMONECTOMY; QUALITY OF LIFE; RADIOTHERAPY DOSAGE; REMISSION INDUCTION; TREATMENT OUTCOME; VINBLASTINE;

EID: 0036806070     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)02943-7     Document Type: Article

References (14)

1. Martini N., Kris M.G., Flehinger B.J., et al. Preoperative chemotherapy for Stage IIIa (N2) lung cancer The Sloan-Kettering experience with 136 patients . Ann Thorac Surg. 55:1993;1365.
2. Pearson F.G., Delarue N.C., Ilves R., et al. Significance of positive superior mediastinal lymph nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg. 83:1982;1-11.
3. Radiation Therapy Oncology Group Eastern Cooperative Oncology Group Southwest Oncology Group, Sause W., Kolesar P., Taylor S. IV, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Chest. 117:2000;358-364.
4. Rosell R., Gomez-Codina T., Camps C., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med. 330:1994;153-158.
5. Roth J., Fosselle F., Komaki R., et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage III non-small cell lung cancer. J Natl Cancer Inst. 86:1994;673-680.
6. Rusch V., Albain K.S., Crowley J.J., et al. Surgical resection of stage IIA and IIIB non-small cell lung cancer after concurrent induction chemoradiotherapy A Southwest Oncology Group Trial . J Thor Cardiovasc Surg. 105:1993;97-106.
7. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
8. Mountain C.F., Dresler C.M. Chest. 111:1997;1718-1723.
9. Ruckdeschel J.C., Wagner H., Robinson L.A. Locally advanced lung cancer Controversies in management . Am Soc Clin Oncol. 220:1996;228.
10. Albain K.S., Rusch V.W., Crowley J.J., et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer Mature results of Southwest Oncology Group Phase II Study 8805 . J Clin Oncol. 13:1995;1880-1892.
11. Shepherd F.A., Johnston M.R., Payne D., et al. Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small cell lung cancer A National Cancer Institute of Canada Clinical Trials Group study . Br J Cancer. 78:1998;683-685.
12. Cox J.D., Azarnia N., Byhardt R.W., et al. N2 (clinical) non-small cell carcinoma of the lung Prospective trials of radiation therapy with total doses of 60 Gy by the Radiation Therapy Oncology Group . Int J Radiat Oncol Biol Phys. 20:1991;7-12.
13. Cox J.D., Azarnia N., Byhardt R.W., et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60 Gy to 79.2 Gy Possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Stage III non-small cell lung cancer - Report of Radiation Therapy Oncology Group 83-11 . J Clin Oncol. 8:1990;1543-1555.
14. Greco F.A. Multidisciplinary approach to potentially curable non-small cell carcinoma of the lung. Oncology. 11:1997;27-49.